Department of Anesthesiology
Author [ Title(Asc)] Type Year
Filters: First Letter Of Last Name is H  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
D
Matovcik LM, Hemmings HC, Kinder BK.  1995.  DARPP-32 (dopamine and cAMP-regulated phosphoprotein, M(r) 32,000) is a membrane protein in the bovine parathyroid.. FEBS Lett. 364(1):67-74.
Hökfelt T, Foster G, Schultzberg M, Meister B, Schalling M, Goldstein M, Hemmings HC, Ouimet C, Greengard P.  1988.  DARPP-32 as a marker for D-1 dopaminoceptive cells in the rat brain: prenatal development and presence in glial elements (tanycytes) in the basal hypothalamus.. Adv Exp Med Biol. 235:65-82.
Hökfelt T, Foster G, Schultzberg M, Meister B, Schalling M, Goldstein M, Hemmings HC, Ouimet C, Greengard P.  1988.  DARPP-32 as a marker for D-1 dopaminoceptive cells in the rat brain: prenatal development and presence in glial elements (tanycytes) in the basal hypothalamus.. Adv Exp Med Biol. 235:65-82.
Nairn AC, Hemmings HC, Walaas SI, Greengard P.  1988.  DARPP-32 and phosphatase inhibitor-1, two structurally related inhibitors of protein phosphatase-1, are both present in striatonigral neurons.. J Neurochem. 50(1):257-62.
Hemmings HC, Greengard P.  1986.  DARPP-32, a dopamine-regulated phosphoprotein.. Prog Brain Res. 69:149-59.
Hemmings HC, Greengard P, Tung HY, Cohen P.  1984.  DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1.. Nature. 310(5977):503-5.
Williams KR, Hemmings HC, LoPresti MB, Konigsberg WH, Greengard P.  1986.  DARPP-32, a dopamine- and cyclic AMP-regulated neuronal phosphoprotein. Primary structure and homology with protein phosphatase inhibitor-1.. J Biol Chem. 261(4):1890-903.
Ouimet CC, Miller PE, Hemmings HC, Walaas SI, Greengard P.  1984.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization.. J Neurosci. 4(1):111-24.
Hemmings HC, Nairn AC, Aswad DW, Greengard P.  1984.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. II. Purification and characterization of the phosphoprotein from bovine caudate nucleus.. J Neurosci. 4(1):99-110.
Hemmings HC, Greengard P.  1986.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein: regional, tissue, and phylogenetic distribution.. J Neurosci. 6(5):1469-81.
Hemmings HC, Williams KR, Konigsberg WH, Greengard P.  1984.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated neuronal phosphoprotein. I. Amino acid sequence around the phosphorylated threonine.. J Biol Chem. 259(23):14486-90.
Hemmings HC, Nairn AC, Greengard P.  1984.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated neuronal phosphoprotein. II. Comparison of the kinetics of phosphorylation of DARPP-32 and phosphatase inhibitor 1.. J Biol Chem. 259(23):14491-7.
Hotte M, Thuault S, Lachaise F, Dineley KT, Hemmings HC, Nairn AC, Jay TM.  2006.  D1 receptor modulation of memory retrieval performance is associated with changes in pCREB and pDARPP-32 in rat prefrontal cortex.. Behav Brain Res. 171(1):127-33.
Hotte M, Thuault S, Lachaise F, Dineley KT, Hemmings HC, Nairn AC, Jay TM.  2006.  D1 receptor modulation of memory retrieval performance is associated with changes in pCREB and pDARPP-32 in rat prefrontal cortex.. Behav Brain Res. 171(1):127-33.
C
Sunaga H, Malhotra JK, Yoon E, Savarese JJ, Heerdt PM.  2010.  Cysteine reversal of the novel neuromuscular blocking drug CW002 in dogs: pharmacodynamics, acute cardiovascular effects, and preliminary toxicology.. Anesthesiology. 112(4):900-9.
Horn CC, Zhurov Y, Orekhova IV, Proekt A, Kupfermann I, Weiss KR, Brezina V.  2004.  Cycle-to-cycle variability of neuromuscular activity in Aplysia feeding behavior.. J Neurophysiol. 92(1):157-80.
Pan S, Gries K, Engel BD, Schroda M, Haselwandter CA, Scheuring S.  2024.  The cyanobacterial protein VIPP1 forms ESCRT-III-like structures on lipid bilayers.. Nat Struct Mol Biol.
Yener U, Pritzlaff SG, Schatman ME, Naeimi T, Argoff CE, Ahadian F, Rosenquist EWK, Hunter CW, Emerick TD, Ciftci HBegum et al..  2026.  The Current Scope of Pain Medicine Fellowships: A Cross-Sectional Survey Study of Trainees, Directors, and Employers on Shaping Future Leaders.. J Pain Res. 19:598637.
Deon D, Ahmed S, Tai K, Scaletta N, Herrero C, Lee IH, Krause A, Ivashkiv LB.  2001.  Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts.. J Immunol. 167(9):5395-403.
Nguyen H, Mount J, Hutchinson K, Zhao Y, Zhao Y, Glaaser IW, Yuan P, Schlessinger A, Slesinger PA.  2026.  A critical residue mediates proper assembly and gating of GIRK2 channels.. J Gen Physiol. 158(1)
Watson SL, McCoy JG, Stavisky RC, Greer TF, Hanbury D.  2005.  Cortisol response to relocation stress in Garnett's bushbaby (Otolemur garnettii).. Contemp Top Lab Anim Sci. 44(3):22-4.
Fitch W, Smith G, Hunter JM, Reilly CS, Mahajan RP, Hemmings HC.  2023.  Corrigendum to 'The evolution of the British Journal of Anaesthesia: the first 100 years' [Br J Anaesth 2023; 130: 3-7].. Br J Anaesth.
Fitch W, Smith G, Hunter JM, Reilly CS, Mahajan RP, Hemmings HC.  2023.  Corrigendum to 'The evolution of the British Journal of Anaesthesia: the first 100 years' [Br J Anaesth 2023; 130: 3-7].. Br J Anaesth.
Rouxel P, Rayon E, Bellocq A-S, Le Guen M, Fessler J, Cirenei C, Blondonnet R, Parfait E, Patrubani A-G, Ramorasata A et al..  2025.  Corrigendum to 'Pain intensity after robotic-assisted urological surgery: The PAIROU study an international prospective cohort study' [ACCPM (2025) 101546].. Anaesth Crit Care Pain Med. 44(5):101594.
Rouxel P, Rayon E, Bellocq A-S, Le Guen M, Fessler J, Cirenei C, Blondonnet R, Parfait E, Patrubani A-G, Ramorasata A et al..  2025.  Corrigendum to 'Pain intensity after robotic-assisted urological surgery: The PAIROU study an international prospective cohort study' [ACCPM (2025) 101546].. Anaesth Crit Care Pain Med. 44(5):101594.